Phenotyping and Classifying Asthma Exacerbations (NCT05304039) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Phenotyping and Classifying Asthma Exacerbations
Netherlands200 participantsStarted 2022-09-28
Plain-language summary
An observational study in patients between 12 and 70 years old with an acute asthma exacerbation, to determine the relation between phenotypical characteristics and the treatment response.
Who can participate
Age range12 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient diagnosed with asthma according to the GINA guidelines between 12 and 70 years old. If patients are doctor's diagnosed with asthma based on clinical data, the further diagnostics will be performed to confirm the asthma diagnosis after the AAE.
* Mild to severe asthma, treated according to GINA guidelines with medium - or high dose inhaled corticosteroids (with or without LABA) or treated with a low dose inhaled corticosteroids combined LABA or leukotriene - receptor antagonist.
* Asthma exacerbation, indicated for systemic corticosteroids.
* Written personal and/or parental informed consent, prior to any study procedures.
* Eligibility and willingness to present during an asthma exacerbation at the Franciscus Gasthuis hospital.
* Ability to use e - health applications.
Exclusion Criteria:
* Immunosuppressive maintenance medication (azithromycin, systemic corticosteroids maintenance therapy and other) or recently (\< 6 weeks) discontinued these medications. (Desensitization therapy indicated for allergies can be included in the study)
* Maintenance medication or recently discontinued (\< 6 weeks) biologicals.
* Other underlying inflammatory or auto-immune diseases, such as rheumatologic disease.
* Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)
* Pregnancy, because of the possible altered immunological status.(31)
* Participation in an interventional study or randomised…
What they're measuring
1
Relation of phenotypical characteristics with treatment response